Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Gossamer Bio stock

Own Gossamer Bio stock in just a few minutes.

Gossamer Bio, Inc is a biotechnology business based in the US. Gossamer Bio shares (GOSS) are listed on the NASDAQ and all prices are listed in US Dollars. Gossamer Bio employs 195 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Gossamer Bio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GOSS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Gossamer Bio share price

Use our graph to track the performance of GOSS stocks over time.

Gossamer Bio shares at a glance

Information last updated 2021-04-29.
52-week range$7.92 - $16.79
50-day moving average $9.12
200-day moving average $9.67
Wall St. target price$21.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.95

Buy Gossamer Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Gossamer Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gossamer Bio financials

Gross profit TTM $0
Return on assets TTM -27.25%
Return on equity TTM -72.3%
Profit margin 0%
Book value $4.55
Market capitalisation $640.7 million

TTM: trailing 12 months

Shorting Gossamer Bio shares

There are currently 11.2 million Gossamer Bio shares held short by investors – that's known as Gossamer Bio's "short interest". This figure is 1.2% up from 11.1 million last month.

There are a few different ways that this level of interest in shorting Gossamer Bio shares can be evaluated.

Gossamer Bio's "short interest ratio" (SIR)

Gossamer Bio's "short interest ratio" (SIR) is the quantity of Gossamer Bio shares currently shorted divided by the average quantity of Gossamer Bio shares traded daily (recently around 660163.71681416). Gossamer Bio's SIR currently stands at 16.95. In other words for every 100,000 Gossamer Bio shares traded daily on the market, roughly 16950 shares are currently held short.

However Gossamer Bio's short interest can also be evaluated against the total number of Gossamer Bio shares, or, against the total number of tradable Gossamer Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gossamer Bio's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Gossamer Bio shares in existence, roughly 150 shares are currently held short) or 0.1886% of the tradable shares (for every 100,000 tradable Gossamer Bio shares, roughly 189 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Gossamer Bio.

Find out more about how you can short Gossamer Bio stock.

Gossamer Bio share dividends

We're not expecting Gossamer Bio to pay a dividend over the next 12 months.

Gossamer Bio share price volatility

Over the last 12 months, Gossamer Bio's shares have ranged in value from as little as $7.92 up to $16.79. A popular way to gauge a stock's volatility is its "beta".

GOSS.US volatility(beta: 1.27)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gossamer Bio's is 1.2715. This would suggest that Gossamer Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Gossamer Bio overview

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site